Literature DB >> 23474473

Assessment of the quality of life of patients with cutaneous leishmaniasis in Belo Horizonte, Brazil, 2009-2010. A pilot study.

Antonio Carlos de Castro Toledo1, Rosiana Estéfane da Silva, Rose Ferraz Carmo, Thaís Alves Amaral, Zélia Maria Profeta Luz, Ana Rabello.   

Abstract

BACKGROUND: Cutaneous leishmaniasis (CL) may manifest as single or multiple skin lesions, causing significant aesthetic impact and affecting the patient's quality of life (QoL). The objective of this study was to assess the impact of CL on the QoL.
METHODS: The QoL of 20 patients with CL was assessed by the Dermatology Life Quality Index (DLQI).
RESULTS: For 70% of patients CL had a moderate/large impact on their QoL, with 'Work and School' being the most affected domain. This is the first study to use the DLQI to assess the impact of CL.
CONCLUSION: CL has a moderate to large negative effect on QoL.

Entities:  

Mesh:

Year:  2013        PMID: 23474473     DOI: 10.1093/trstmh/trt021

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  14 in total

1.  Cutaneous leishmaniasis in Sri Lanka: effect on quality of life.

Authors:  Wardha F Refai; Nayani P Madarasingha; Buthsiri Sumanasena; Sudath Weerasingha; Rohini Fernandopulle; Nadira D Karunaweera
Journal:  Int J Dermatol       Date:  2018-09-23       Impact factor: 2.736

2.  Randomized single-blinded non-inferiority trial of 7 mg/kg pentamidine isethionate versus 4 mg/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname.

Authors:  Ricardo V P F Hu; Masja Straetemans; Alida D Kent; Leslie O A Sabajo; Henry J C de Vries; Rudy F M Lai A Fat
Journal:  PLoS Negl Trop Dis       Date:  2015-03-20

3.  Assessment of psychiatric morbidity and quality of life in children and adolescents with cutaneous leishmaniasis and their parents.

Authors:  Enver Turan; Hasan Kandemir; Yavuz Yeşilova; Suat Ekinci; Osman Tanrıkulu; Sultan Basmacı Kandemir; Mehmet Salih Gurel
Journal:  Postepy Dermatol Alergol       Date:  2015-10-29       Impact factor: 1.837

4.  Assessment of quality of life in patients with post kalaazar dermal leishmaniasis.

Authors:  Biplab Pal; Krishna Murti; Niyamat Ali Siddiqui; Pradeep Das; Chandra Shekhar Lal; Rajendra Babu; Manoj Kumar Rastogi; Krishna Pandey
Journal:  Health Qual Life Outcomes       Date:  2017-07-24       Impact factor: 3.186

5.  Development and initial validation of a cutaneous leishmaniasis impact questionnaire.

Authors:  Endi Lanza Galvão; Mariana Junqueira Pedras; Gláucia Fernandes Cota; Taynãna César Simões; Ana Rabello
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

6.  Leishmaniasis patients' pilgrimage to access health care in rural Bolivia: a qualitative study using human rights to health approach.

Authors:  Daniel Eid; Miguel San Sebastian; Anna-Karin Hurtig; Isabel Goicolea
Journal:  BMC Int Health Hum Rights       Date:  2019-03-05

7.  Interventions for American cutaneous and mucocutaneous leishmaniasis.

Authors:  Mariona Pinart; José-Ramón Rueda; Gustavo As Romero; Carlos Eduardo Pinzón-Flórez; Karime Osorio-Arango; Ana Nilce Silveira Maia-Elkhoury; Ludovic Reveiz; Vanessa M Elias; John A Tweed
Journal:  Cochrane Database Syst Rev       Date:  2020-08-27

Review 8.  Psychosocial burden of localised cutaneous Leishmaniasis: a scoping review.

Authors:  Issam Bennis; Vincent De Brouwere; Zakaria Belrhiti; Hamid Sahibi; Marleen Boelaert
Journal:  BMC Public Health       Date:  2018-03-15       Impact factor: 3.295

9.  Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates.

Authors:  Freddie Bailey; Karina Mondragon-Shem; Lee Rafuse Haines; Amina Olabi; Ahmed Alorfi; José Antonio Ruiz-Postigo; Jorge Alvar; Peter Hotez; Emily R Adams; Iván D Vélez; Waleed Al-Salem; Julian Eaton; Álvaro Acosta-Serrano; David H Molyneux
Journal:  PLoS Negl Trop Dis       Date:  2019-02-25

10.  How cutaneous leishmaniasis and treatment impacts in the patients' lives: A cross-sectional study.

Authors:  Endi Lanza Galvão; Mariana Junqueira Pedras; Gláucia Fernandes Cota; Ana Rabello; Taynãna César Simões
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.